Registration and Quality Assurance of ARVs and Other essential Medicines in Namibia

Nasser Mbaziira

September 2015
This report is made possible by the generous support of the American people through the US Agency for International Development (USAID), under the terms of cooperative agreement number AID-OAA- A-11-00021. The contents are the responsibility of Management Sciences for Health and do not necessarily reflect the views of USAID or the United States Government.

About SIAPS

The goal of the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program is to assure the availability of quality pharmaceutical products and effective pharmaceutical services to achieve desired health outcomes. Toward this end, the SIAPS result areas include improving governance, building capacity for pharmaceutical management and services, addressing information needed for decision-making in the pharmaceutical sector, strengthening financing strategies and mechanisms to improve access to medicines, and increasing quality pharmaceutical services.

Recommended Citation

This report may be reproduced if credit is given to SIAPS. Please use the following citation.


Key Words

Medicine regulation, medicines registration, dossiers, Post market surveillance

Systems for Improved Access to Pharmaceuticals and Services
Center for Pharmaceutical Management
Management Sciences for Health
4301 North Fairfax Drive, Suite 400
Arlington, VA 22203 USA
Telephone: 703.524.6575
Fax: 703.524.7898
E-mail: siaps@msh.org
Website: www.siapsprogram.org
# Table of Contents

List of Figures ................................................................................................................................. v
List of Tables .................................................................................................................................. v
Acknowledgements ........................................................................................................................ vi
Acronyms and Abbreviations .......................................................................................................... 7
1.0 Background .................................................................................................................................. 8
2.0 Interventions ................................................................................................................................ 11
3.0 Results/Outcomes .................................................................................................................... 12
5.0 Conclusions ............................................................................................................................. 16
5.0 References .................................................................................................................................. 17
6.0 Appendices .................................................................................................................................. 18
List of Figures
Figure 1: Number of received and unevaluated/backlog dossier dossiers at NMRC 2011-2014... 9
Figure 2: Percentage of dossiers evaluated against those received by NMRC......................... 9
Figure 3: Trends in medicine registration application backlog .................................................... 12
Figure 4: Number of samples collected by generic name categories........................................ 13
Figure 5: Number of samples collected by region ................................................................. 13
Figure 6: Percentage of failures by product category............................................................... 15
Figure 7: Number of sample failures by analytical parameters............................................. 15

List of Tables
Table 1: Category of medicine samples targeted................................................................. 11
Table 3: Percentage of samples with results from NMRC Quality Surveillance Laboratory..... 14
Table 4: Sample results by region....................................................................................... 14
ACKNOWLEDGEMENTS

The author wishes to acknowledge the staff of the Namibia Medicines Regulatory Council (NMRC) secretariat for their efforts, dedication and enthusiasm that led to the achievements of medicines regulation functions in this period.

I am also grateful to the Registrar of NMRC, Mr. Johannes Gaeseb for the time and support provided throughout the implementation of technical assistance activities for medicines regulation.

I acknowledge the management, technical and operations/administration staff of SIAPS in Namibia for the support rendered in implementation of the activities in this report.

Last but not least, I would like to acknowledge the financial support provided by PEPFAR through USAID without which implementation of the activities in the period would not have been possible.
ACRONYMS AND ABBREVIATIONS

3TC   Lamivudine
ADE   Adverse Drug Events
AIDS  Acquired Immunodeficiency Syndrome
ART   Antiretroviral Therapy
ARVs  Antiretrovirals
AZT   Zidovudine
FTC   Emtricitabine
EFV   Efavirenz
GMP   Good Manufacturing Practices
HIV   Human Immunodeficiency Virus
MoHSS Ministry of Health and Social Services
NMRC  Namibia Medicines Regulatory Council
NVP   Nevirapine
PMS   Post Market Surveillance
QSL   Quality Surveillance Laboratory
RPM   Rational Pharmaceutical Management
SIAPS System for Improved Access to Pharmaceuticals and Services
SPS   Strengthening Pharmaceutical Systems
STA   Senior Technical Advisor
TA    Technical Assistance
TB    Tuberculosis
TDF   Tenofovir Disoproxil Fumarate
TIPC  Therapeutics Information and Pharmacovigilance Centre
USAID United States Agency for International Development
WHO   World Health Organization
1.0 BACKGROUND

Namibia’s estimated population of 2.3 million people is distributed unevenly in urban centers and rural communities and has a sparse population density of 2.6 people/square kilometers. Namibia is one of the Africa countries significantly affected by the HIV & AIDS epidemic, which is one the leading causes of morbidity and mortality in the country. The adult HIV prevalence rate is estimated at about 14.2%, and about 140,000 patients were on ART program as at March 2015.

Namibia Medicine Regulatory Council (NMRC) is mandated to ensure quality, safety and efficacy of medicines, and contribute to improving treatment outcomes; the health of Namibia’s population and economy. Among the key functions of NMRC; to conduct technical assessment of medicine application prior to medicine registration and post-market surveillance to monitor quality of registered medicines in the country.

Namibia’s NMRC secretariat has greatly benefited from the technical and financial support through various USAID-funded projects; Rational Pharmaceutical Management Plus (RPM plus), Strengthening Pharmaceutical Systems (SPS) and currently Systems for Improved Access to Pharmaceuticals and Services (SIAPS) project. All the projects aimed at improving and strengthening NMRC’s capacity to efficiently and effectively perform its statutory regulatory functions to support the HIV&AIDS and other public health services, through ensuring quality, safety and efficacy Antiretroviral (ARV) and other essential medicines for the Antiretroviral Treatment (ART) program. The technical functions of NMRC supported over the years included; registration, inspection and licensing, quality surveillance and therapeutic information and pharmacovigilance.

For a long time, the effectiveness of NMRC’s functionality was greatly limited largely due human and technical resource constraints. The challenges largely contributed to the rapid growth of the number of unassessed medicine applications/dossiers to 746 dossiers by March 2014 and the longer periods between receipt of a dossier and responding to clients on the review outcomes. This had a big impact on the HIV commodities supply chain since new ARVs, which were not yet registered could not easily be procured and stocked by the central medical stores, and the quality, safety & efficacy of those that got waivers could not be guaranteed.

Figure1 below illustrates the trends of the backlog over a four year period; where on average over 40% of the received dossiers were not reviewed, 64% (2011), 49% (2012), 44% (2013) and 45% by September 2014.
Figure 1: Number of received and unevaluated/backlog dossier dossiers at NMRC 2011-2014.

Through SIAPS support in the previous years, an improvement in the proportion of application dossiers reviewed on annual basis has been realized as shown in figure 2.

Figure 2: Percentage of dossiers evaluated against those received by NMRC.

The SIAPS supported interventions in FY14 included capacity building through training and mentoring, also priority was given to applications that constituted the three year (2010 - 2013) backlog of over 550 applications.

At NMRC, the Therapeutics Information and Pharmacovigilance Centre (TIPC) relatively performs well to maintain an effective pharmacovigilance system especially in the domains of Adverse drug reactions/events (ADR) monitoring and disseminating information on medicines usage to Namibian health care providers for patient safety. However, the domain of monitoring quality of medicines in the public healthcare medicines supply chain to rule out counterfeit and substandard medicines was still a challenge, which could pose a risk of
circulation of substandard and counterfeit pharmaceuticals that may negatively affect treatment outcomes for HIV and AIDS, tuberculosis (TB) and other diseases
2.0 INTERVENTIONS

TA for expedited registration and introduction of newly recommended ARV formulations (including pediatric formulations):

In FY15, SIAPS continued to provide TA to facilitate the expedited assessment and registration of new and other ARV formulations to support the implementation of the revised Namibian ART guidelines (dated January 2014). The TA targeted improving the efficiency of the regulatory system so that the recommend new first-line fixed-dose combination (FDC) ARVs that contain tenofovir and emtricitabine for adults; and optimized ARV formulations for pediatric use, other medicines for HIV and AIDS, TB, maternal newborn and child health (MNCH), and other public health diseases are assessed and considered for registration and made available for public procurement in a timely manner to the benefit of patients on the ART program.

SIAPS provided technical assistance (TA) in the form of mentoring and on-going on-the-job training to five new staff at NMRC and other personnel engaged in evaluation of dossiers for registration of ARV medicines, including new pediatric formulations and other essential medicines. This was conducted under organized dossier evaluation sessions, which was gradually transition to NMRC for sustainability and continued improvement of institution’s efficiency in its operations.

To further ensure quality, safe and efficacy of HIV&AIDS, TB, and MNCH and other essential medicines post registration, NMRC with support of the USAID-funded SIAPS project developed medicines quality monitoring guidelines, and in FY15, NMRC in collaboration with SIAPS conducted a baseline survey on the quality of ARVs, tuberculosis and other essential medicines in public health facilities using the newly developed guidelines. The activity benefitted eight (57%) of the 14 regions (Kavango East & West considered as one region) in the country, and samples were tested by the national quality surveillance laboratory (QSL) and those failing the pharmacopoeial tests were forwarded to a WHO prequalified laboratory for confirmatory testing. Table 1 shows the scope of samples collected.

<table>
<thead>
<tr>
<th>#</th>
<th>Category</th>
<th>Generic Name</th>
<th>Strength</th>
<th>Dosage form</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ARV</td>
<td>Abacavir/ Lamivudine (ABC/3TC)</td>
<td>60mg/30mg</td>
<td>Tablets</td>
</tr>
<tr>
<td>2</td>
<td>OI</td>
<td>Amoxicillin</td>
<td>250mg</td>
<td>Capsules</td>
</tr>
<tr>
<td>3</td>
<td>OI</td>
<td>Amoxicillin</td>
<td>125mg/ml</td>
<td>Suspension</td>
</tr>
<tr>
<td>4</td>
<td>OI</td>
<td>Amoxicillin/Clavulanic Acid</td>
<td>1000mg</td>
<td>Tablets</td>
</tr>
<tr>
<td>5</td>
<td>OI</td>
<td>Cefuroxime Axetil</td>
<td>125mg/5ml</td>
<td>Suspension</td>
</tr>
<tr>
<td>6</td>
<td>OI</td>
<td>Cefuroxime Axetil</td>
<td>250mg</td>
<td>Tablets</td>
</tr>
<tr>
<td>7</td>
<td>OI</td>
<td>Co-trimoxazole</td>
<td>240mg/5ml</td>
<td>Suspension</td>
</tr>
<tr>
<td>8</td>
<td>OI</td>
<td>Co-trimoxazole</td>
<td>480mg</td>
<td>Tablets</td>
</tr>
<tr>
<td>9</td>
<td>ARV</td>
<td>Lamivudine/Zidovudine (3TC/AZT)</td>
<td>150mg/300mg</td>
<td>Tablets</td>
</tr>
<tr>
<td>10</td>
<td>ARV</td>
<td>Lamivudine/Zidovudine (3TC/AZT)</td>
<td>30mg/60mg</td>
<td>Tablets</td>
</tr>
<tr>
<td>11</td>
<td>Others</td>
<td>Metformin</td>
<td>500mg</td>
<td>Tablets</td>
</tr>
<tr>
<td>12</td>
<td>ARV</td>
<td>Nevirapine (NVP)</td>
<td>50mg/ml</td>
<td>Oral solution</td>
</tr>
<tr>
<td>13</td>
<td>ARV</td>
<td>Nevirapine (NVP)</td>
<td>200mg</td>
<td>Tablets</td>
</tr>
<tr>
<td>14</td>
<td>Others</td>
<td>Perindopril</td>
<td>4mg</td>
<td>Tablets</td>
</tr>
</tbody>
</table>
3.0 RESULTS/OUTCOMES

Performance of NMRC medicine registration function.

In October 2014, SIAPS continued to support NMRC and organized a dossier evaluation session primarily aimed at mentoring and improving dossier evaluation skills for the newly recruited NMRC staff and reduce the dossier backlog. A total of 132 medicine registration applications received in 2012 and part of 2011 were reviewed. This activity has been successfully transitioned to NMRC, and in FY15 four evaluation sessions (February, June and September 2015) were solely organized by NMRC and this has greatly contributed to a remarkable reduction in the numbers and age of the backlog.

Figure 3: Trends in medicine registration application backlog

There has been a significant reduction in the number and age of the dossier backlog at NMRC as shown in figure 3. A total of 711 applications received in 2011 to 2014 had not been evaluated for registration by September 2014 (FY14) compared to 100 applications as at September 2015 (FY15), reflecting an 86% reduction of the backlog up to September 2014. The age of the backlog has also reduced significantly; > three years (38%→3%), > two years (24%→2%), > one year (18%→1%) and < one year (19%→8%). And 40% of the dossiers received in running year, 2015 were reviewed.

As of August 2015, a total of 6064 pharmaceutical products were registered for use and the average number of days taken to review and approve a medicine registration application reduced from over 53 days to 48 days in 2014.
Post Market Surveillance – Medicine quality monitoring

A total of 171 samples of ARVs, TB and other essential medicines were collected from 24 public health facilities in eight regions. The facilities included seven primary healthcare clinics, six health centers, six district hospitals and one intermediate hospital. Figures 4 & 5 show the total number of samples collected categorized by generic name and region respectively.

Figure 4: Number of samples collected by generic name categories

Figure 5: Number of samples collected by region.
Table 3 shows the improved capacity of QSL to test medicine samples. The laboratory was able to test and release results of 88% (151) of the samples collected. This may be partly attributed to SAIPS support towards human capacity development for NMRC in FY14. Also there was a challenge of availability of reference standards for samples with zero percent rate.

Table 2: Percentage of samples with results from NMRC Quality Surveillance Laboratory

<table>
<thead>
<tr>
<th>#</th>
<th>Generic Name</th>
<th>Strength</th>
<th>Dosage form</th>
<th># of samples</th>
<th>% results received</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ABC/3TC</td>
<td>60mg/30mg</td>
<td>Tablets</td>
<td>3</td>
<td>0%</td>
</tr>
<tr>
<td>2</td>
<td>Amoxicillin</td>
<td>250mg</td>
<td>Capsules</td>
<td>21</td>
<td>95%</td>
</tr>
<tr>
<td>3</td>
<td>Amoxicillin</td>
<td>125mg/ml</td>
<td>Suspension</td>
<td>16</td>
<td>88%</td>
</tr>
<tr>
<td>4</td>
<td>Amoxicillin/Clavulanic Acid</td>
<td>1000mg</td>
<td>Tablets</td>
<td>5</td>
<td>100%</td>
</tr>
<tr>
<td>5</td>
<td>Cefuroxime Axetil</td>
<td>125mg/5ml</td>
<td>Suspension</td>
<td>6</td>
<td>100%</td>
</tr>
<tr>
<td>6</td>
<td>Cefuroxime Axetil</td>
<td>250mg</td>
<td>Tablets</td>
<td>5</td>
<td>100%</td>
</tr>
<tr>
<td>7</td>
<td>Co-trimoxazole</td>
<td>240mg/5ml</td>
<td>Suspension</td>
<td>17</td>
<td>94%</td>
</tr>
<tr>
<td>8</td>
<td>Co-trimoxazole</td>
<td>480mg</td>
<td>Tablets</td>
<td>24</td>
<td>100%</td>
</tr>
<tr>
<td>9</td>
<td>3TC/AZT</td>
<td>150mg/300mg</td>
<td>Tablets</td>
<td>13</td>
<td>77%</td>
</tr>
<tr>
<td>10</td>
<td>3TC/AZT</td>
<td>30mg/60mg</td>
<td>Tablets</td>
<td>5</td>
<td>100%</td>
</tr>
<tr>
<td>11</td>
<td>Metformin</td>
<td>500mg</td>
<td>Tablets</td>
<td>12</td>
<td>100%</td>
</tr>
<tr>
<td>12</td>
<td>NVP</td>
<td>50mg/ml</td>
<td>Oral solution</td>
<td>8</td>
<td>100%</td>
</tr>
<tr>
<td>13</td>
<td>NVP</td>
<td>200mg</td>
<td>Tablets</td>
<td>14</td>
<td>86%</td>
</tr>
<tr>
<td>14</td>
<td>Perindopril</td>
<td>4mg</td>
<td>Tablets</td>
<td>8</td>
<td>0%</td>
</tr>
<tr>
<td>15</td>
<td>RHZE</td>
<td>150/75/400/275mg</td>
<td>Tablets</td>
<td>14</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td><strong>171</strong></td>
<td><strong>88%</strong></td>
</tr>
</tbody>
</table>

Of the 151 samples tested, 13.9% (21) did not conform to pharmacopoeial specifications and Table 4 illustrates the results of the samples by region. Notably, 36.8% of the samples were unregistered, of which 1.9% were sub-standard according to the results from QSL and a WHO prequalified laboratory.

Table 3: Sample results by region

<table>
<thead>
<tr>
<th>Regions</th>
<th>Passed</th>
<th>Failed</th>
<th>Not tested</th>
<th>Grand Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erongo</td>
<td>8</td>
<td>1 (11%)</td>
<td>3</td>
<td>12</td>
</tr>
<tr>
<td>Karas</td>
<td>14</td>
<td>3 (18%)</td>
<td>1</td>
<td>18</td>
</tr>
<tr>
<td>Kavango</td>
<td>12</td>
<td>4 (25%)</td>
<td>7</td>
<td>23</td>
</tr>
<tr>
<td>Ohangwena</td>
<td>24</td>
<td>1 (4%)</td>
<td>3</td>
<td>28</td>
</tr>
<tr>
<td>Oshana</td>
<td>33</td>
<td>6 (15%)</td>
<td>1</td>
<td>40</td>
</tr>
<tr>
<td>Oshikoto</td>
<td>16</td>
<td>3 (16%)</td>
<td>4</td>
<td>23</td>
</tr>
<tr>
<td>Otjozondjupa</td>
<td>19</td>
<td>2 (10%)</td>
<td>1</td>
<td>22</td>
</tr>
<tr>
<td>Zambezi</td>
<td>4</td>
<td>1 (20%)</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td><strong>Grand Total</strong></td>
<td><strong>130</strong></td>
<td><strong>21</strong></td>
<td><strong>22</strong></td>
<td><strong>172</strong></td>
</tr>
</tbody>
</table>
Figure 6: Percentage of failures by product category

From figure 6 above, Co-trimoxazole suspension registered the highest percent of failures (100%), followed by Co-trimoxazole tablets (17%) and Amoxicillin suspension (7%). All the other products had no failures registered.

Figure 7: Number of sample failures by analytical parameters.

Figure 7 shows the nature of failures for the failed samples; 90% (19) failed assay, dissolution and other tests were at 5% (1) each.
5.0 CONCLUSIONS

SIAPS continued TA to NMRC has strengthened the capacity, improved the efficiency and significantly reduced the longtime backlog of medicine registration applications at NMRC. NMRC has taken up financial support for intensified medicines dossier reviews to accelerate the process and shorten the time taken to evaluate applications and register medicines, three of the four (75%) of the dossier review sessions held in FY15 were organized and financed by NMRC, which shows their commitment and sustainability of the interventions supported by the USAID-funded SIAPS project.

NMRC has also taken great strides towards post registration medicine quality monitoring and regulatory decisions are taken based on the outcomes to recall all products that do not conform to specifications, which may lack efficacy and thus impact on treatment outcomes and risk of developing microbial resistance to medicines.
5.0 REFERENCES

6.0 APPENDICES

Appendix I: Official Invitation letter for Participants of Dossier review sessions

REPUBLIC OF NAMIBIA

Ministry of Health and Social Services

Private Bag 1198
Windhoek
Namibia

Enquiry: Ref:

NAMIBIA MEDICINES REGULATORY COUNCIL
OFFICE OF THE REGISTRAR OF MEDICINES

Tel: (061) 203 3407
Fax: (061) 225048
(International 024 61 225048)

Date: 12.08.2014

To:

Dear Sir / Madam

INVITATION TO A DOSSIER EVALUATION RETREAT 19TH – 24TH OCTOBER 2014

The Namibia Medicines Regulatory Council (NMRC) in collaboration with the MoHSS development partner MSH / SIAPS is organizing another dossier evaluation retreat which will be held at the Okahandja Country Hotel at the mentioned dates. The aim of this retreat is to further build the capacity of the attendees to enable them self-evaluate and make a decision on quality of submitted dossiers and is on voluntary basis.

This retreat is a follow up on the dossier evaluation training that was held in Windhoek, 12 – 16th May 2014 (which you attended) and the subsequent successful follow up dossier evaluation retreat conducted in Windhoek on 21 – 25th July 2014.

I am inviting you to attend this important retreat. All expenses, i.e. accommodation and meals, will be covered. All that will be required from you is to be able to bring yourself to and from Okahandja.

If you are interested, please submit your name before or on 15th October 2014 preferably by e-mail to Ms. Saron Kauhondumwa, e-mail drugreg@nmrc.com.na, tel: 061 2032402, fax 061 225 048

"Health for All"

Yours Faithfully,

Joharang #Gaeseb
REGISTRAR OF MEDICINES
Appendix II: Sample photographs taken during NMRC dossier review sessions in FY15

Medicine application dossiers lined up for review during a dossier evaluation session, October 2014. Photo by MSH/Namibia

A new staff of NMRC; Ms. Wubijig Legesse (on the right) reviewing a dossier, October 2014. Photo by MSH/Namibia